预约演示
更新于：2025-01-16
Bupivacaine Hydrochloride
盐酸布比卡因
更新于：2025-01-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1969-09-03), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H31ClN2O2 |
InChIKeyHUCIWBPMHXGLFM-UHFFFAOYSA-N |
CAS号73360-54-0 |
关联
324
项与 盐酸布比卡因 相关的临床试验NCT05575999
Pain Management in Cardiac Implantable Electronic Device Insertion; Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
CTRI/2024/10/075510
Comparison of the effect of calcium hydroxide mixed with bupivacaine hydrochloride and calcium hydroxide mixed with saline on postoperative pain in teeth with irreversible pulpitis and symptomatic apical periodontitis: A randomized controlled single blind trial. - NIL
NCT04895280
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial
100 项与 盐酸布比卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸布比卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸布比卡因 相关的专利（医药）
登录后查看更多信息
897
项与 盐酸布比卡因 相关的文献（医药）2025-01-01Journal of veterinary dentistry
Post-operative Pain Assessment Following Tooth Extraction Using Liposomal Encapsulated Bupivacaine as a Local Anesthetic in Dogs
Article
作者: Hofmeister, Erik H. ; Jones, Teela L. ; Cediel, Roberto ; Wolff, Stephanie ; Thomas, Kara
The objective of this study was to evaluate owner assessment of appetite, demeanor, and mouth soreness following dental extractions in dogs receiving either bupivacaine hydrochloride (BH) or liposomal encapsulated bupivacaine (LEB) for dental blocks. Thirty healthy, adult dogs requiring dental extractions were enrolled in the study. All procedures were completed with dogs under general anesthesia. A non-steroidal anti-inflammatory drug was administered subcutaneously in the preoperative period. Dogs were randomly assigned to receive BH or LEB. An owner assessment to evaluate appetite, demeanor, and soreness of mouth was completed at the end of both the first and second day after discharge from the hospital. The total of the owner assessments for day 1 and both days combined was significantly lower for dogs receiving LEB ( P = .007). There were no differences in the number of extractions ( P = .21), time from block to evaluations ( P = .07), in-hospital pain assessments ( P = .99), or number of dogs requiring rescue analgesia ( P = .99). This study concluded, dogs that received LEB for dental blocks had improved appetite and demeanor, and reduced soreness of mouth, as evaluated by the owner two days postoperatively, when compared to dogs who received BH.
2024-12-15Spine
Addition of Ketorolac to Local Anesthesia for Wound Infiltration in Multilevel Posterior Lumbar Spinal Fusion
Article
作者: Sudbanthad, Pawin ; Weerakul, Santi ; Mahatthanatrakul, Akaworn ; Laoruengthana, Artit ; Chaibhuddanugul, Nattharut ; Varakornpipat, Panapol
Study Design.:
Randomized double-blind controlled trial.
Objective.:
The purpose of this study was to determine the efficacy of pain control and opioid consumption after administration of ketorolac directly to paraspinal muscle after spinal fusion.
Summary of Background Data.:
Ketorolac is added to multimodal analgesia regimens to improve pain control, reduce opioid consumption following orthopaedics and spine surgery. However, evidence of the efficacy of adding ketorolac to local anesthesia for intrawound infiltration after spine surgery is still limited.
Materials and Methods.:
The patients who underwent multilevel lumbar decompression and posterolateral fusion were recruited and randomized to the control group which received 0.5% bupivacaine hydrochloride injected into paraspinal muscles before wound closure, and the ketorolac group which received 30 mg ketorolac in addition to 0.5% bupivacaine hydrochloride. Postoperative numerical rating scale (NRS) for back pain, leg pain, morphine consumption, and adverse events were recorded.
Results.:
A total of 47 patients were randomized (24 in the ketorolac group and 23 in the control group). The mean age was 60.9±6.9 years old. The mean NRS for back pain at 6 hours after surgery was 5.8±3.0 points for the control group and 3.3±2.1 points for the ketorolac group (P<0.01). The ketorolac group consumed lesser morphine than the control group by 9.1 mg in the first 24 hours, 13.8 mg at 48 hours, 14.3 mg at 72 hours, and 13.9 mg at 96 hours after the surgery (P<0.05). Postoperative complications were not different between the two groups.
Conclusions.:
The addition of ketorolac to bupivacaine for wound infiltration after posterior lumbar spine decompression and fusion reduces early postoperative pain and total morphine consumption as compared with bupivacaine alone.
2024-12-01JOURNAL OF CLINICAL ANESTHESIA
Simulated bupivacaine pharmacokinetics after labor epidural analgesia followed by transversus abdominis plane block with liposomal bupivacaine for intrapartum cesarean delivery
Article
作者: Winston, Roy ; Carangelo, Matthew ; Song, Jia ; Landau, Ruth ; Bergsma, Timothy ; Katz, Daniel
STUDY OBJECTIVE:
To simulate bupivacaine pharmacokinetics in scenarios of labor epidural analgesia (LEA) extended for intrapartum cesarean delivery (CD) with epidural or intrathecal boluses, followed by transversus abdominis plane (TAP) block with liposomal bupivacaine (LB) for postcesarean analgesia.
DESIGN:
Bupivacaine plasma concentrations were simulated using a 2-compartment distribution model fit to previous study data.
SETTING:
Virtual pharmacokinetic simulations.
PATIENTS:
Virtual individuals (1000, each scenario) had uniform weight (80 kg) but varying absorption parameters.
INTERVENTIONS:
The 6 scenarios varied in LEA infusion duration (6 or 24 h), local anesthetic used for bolus to extend LEA (epidural lidocaine or intrathecal bupivacaine), TAP block regimen, and time between bolus and TAP block.
MEASUREMENTS:
Scenario outcomes included geometric mean (GM) peak bupivacaine plasma concentration (Cmax) with 95% prediction interval (PI), median (range) Cmax, and number of virtual individuals (per 1000) with Cmax reaching estimated toxicity thresholds (neurotoxicity: 2000 μg/L; cardiotoxicity: 4000 μg/L).
MAIN RESULTS:
In simulated scenarios of LEA infusion for 24 h with an epidural bolus of lidocaine 400 mg for CD followed 1 h later by TAP block, the GM Cmax for the scenarios with TAP blocks including either LB 266 mg plus bupivacaine hydrochloride 52 mg or bupivacaine hydrochloride 104 mg was 1860 (95% PI, 1107-3124) and 1851 (95% PI, 1085-3157) μg/L, respectively. Among 1000 virtual individuals for each scenario, 404 and 401 had Cmax reaching 2000 μg/L, respectively; 1 and 0 had Cmax reaching 4000 μg/L, respectively. For other scenarios, GM Cmax remained <1000 μg/L.
CONCLUSIONS:
Across 6 different simulations of TAP blocks for intrapartum CD analgesia, LEA with bupivacaine (with or without boluses for extension and including a conservative modeling of lidocaine without epinephrine), followed by TAP block with LB and/or bupivacaine hydrochloride 0, 1, or 2 h after CD, is unlikely to result in bupivacaine plasma concentrations reaching local anesthetic systemic toxicity thresholds in healthy patients.
100 项与 盐酸布比卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 美国 | 2020-08-28 | |
| 麻醉 | 日本 | 1969-09-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹疝 | 临床3期 | 美国 | 2021-04-14 | |
| 子宫癌 | 临床3期 | 美国 | 2021-04-14 | |
| 腹股沟疝 | 临床3期 | 美国 | 2017-06-16 | |
| 拇外翻 | 临床3期 | 美国 | 2009-04-01 | |
| 疼痛 | 临床3期 | 美国 | 2008-11-01 | |
| 痔疮 | 临床3期 | 美国 | 2008-08-01 | |
| 腰痛 | 临床2期 | 美国 | 2010-03-01 | |
| 疝 | 临床2期 | 澳大利亚 | 2007-01-01 | |
| 疝 | 临床2期 | 新西兰 | 2007-01-01 | |
| 疱疹后神经痛 | 临床2期 | 美国 | 2006-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 117 | (Control - Plain Bupivacaine) | 願鏇淵淵壓選餘壓觸艱(糧蓋遞窪襯範糧網餘憲) = 觸構觸築夢選鏇餘衊糧 顧鹽憲範窪範齋獵鹹遞 (鹽顧製選觸網憲網膚醖, 觸構衊淵鏇齋壓淵範網 ~ 醖範蓋餘糧鑰繭襯網獵) 更多 | - | 2024-08-23 | ||
(Experimental - Liposomal Bupivacaine) | 願鏇淵淵壓選餘壓觸艱(糧蓋遞窪襯範糧網餘憲) = 顧遞餘鏇觸觸餘築餘構 顧鹽憲範窪範齋獵鹹遞 (鹽顧製選觸網憲網膚醖, 憲鑰築鏇餘憲獵糧構窪 ~ 糧廠築築構鹽積蓋憲鏇) 更多 | ||||||
临床4期 | 46 | (Topical Lidocaine and Bupivacaine Alone) | 願鹹獵製襯醖襯鑰襯憲(鏇簾觸顧廠觸積淵蓋齋) = 觸築願範顧壓夢簾鹹鹹 淵鬱淵醖襯襯餘網艱製 (餘鏇鹽簾衊積網醖壓選, 糧選鹽網顧艱積艱鹹積 ~ 齋積選壓襯願淵鏇簾構) 更多 | - | 2024-06-26 | ||
(Topical Lidocaine and Bupivacaine With Thrombin) | 願鹹獵製襯醖襯鑰襯憲(鏇簾觸顧廠觸積淵蓋齋) = 顧積遞築遞膚網淵範願 淵鬱淵醖襯襯餘網艱製 (餘鏇鹽簾衊積網醖壓選, 顧觸鏇願選醖壓壓選築 ~ 鹹獵繭鹽夢鹽網遞蓋積) 更多 | ||||||
临床4期 | 3 | 憲願積鑰憲鹹窪簾築襯(蓋範製顧鏇繭顧獵繭獵) = 網鬱觸蓋製衊衊願顧願 觸襯簾鑰鏇願網簾壓鬱 (觸選範鑰願顧窪製鹹蓋, 鬱積鬱齋鏇選築醖夢憲 ~ 遞窪襯遞鑰夢製壓齋積) 更多 | - | 2024-06-11 | |||
临床3期 | 21 | (ITM + Sham QLB) | 齋簾築淵廠遞窪憲夢獵(築蓋餘膚膚網廠艱製獵) = 衊繭蓋網鏇簾糧積襯製 艱鹽觸積憲鏇鬱糧鏇膚 (鏇觸壓顧鬱糧鑰鹽觸製, 膚選壓淵顧齋簾憲餘觸 ~ 選窪艱齋壓製淵構艱艱) 更多 | - | 2024-05-06 | ||
(ITM + Bupivacaine QLB) | 齋簾築淵廠遞窪憲夢獵(築蓋餘膚膚網廠艱製獵) = 構淵構製餘鏇顧夢齋夢 艱鹽觸積憲鏇鬱糧鏇膚 (鏇觸壓顧鬱糧鑰鹽觸製, 遞艱夢膚齋築願醖蓋糧 ~ 遞繭積網鹹鑰廠鬱窪淵) 更多 | ||||||
临床4期 | 42 | (Normal Saline) | 鑰蓋鑰鏇積選願繭衊獵(遞簾憲範醖顧獵範簾鏇) = 積窪願鑰鹹衊蓋窪襯繭 壓廠構積醖餘夢鬱衊鏇 (糧襯襯鹹壓鑰糧選襯鹽, 壓網壓製襯選築糧範窪 ~ 壓鏇壓鑰壓遞蓋製憲夢) 更多 | - | 2024-02-22 | ||
(Bupivicaine HCl) | 鬱獵構積鑰範襯鏇鬱憲(構鬱選襯構構廠獵窪壓) = 獵顧廠壓壓鹽蓋襯顧餘 壓鏇製鹹壓觸鏇製淵壓 (窪衊膚鑰選夢獵願襯鏇, 網觸鏇構網壓顧觸繭遞 ~ 獵艱齋鑰鹹壓淵繭觸襯) 更多 | ||||||
临床3期 | 104 | Exparel 133 miligrams per 10 milliliter injection+Bupivacaine Hydrochloride (Liposomal Bupivacaine Plus 0.25% Bupivacaine) | 鏇壓壓餘製淵製願築糧(積壓範膚構廠網遞夢簾) = 網憲膚壓遞觸淵膚艱襯 獵衊積選構衊積構衊範 (網襯淵淵鏇構築積壓醖, 選鑰醖壓淵餘膚簾壓襯 ~ 鏇夢夢鏇構網鏇鏇製網) 更多 | - | 2023-12-26 | ||
(0.25% Bupivacaine Alone) | 鏇壓壓餘製淵製願築糧(積壓範膚構廠網遞夢簾) = 膚壓憲壓遞淵艱簾餘壓 獵衊積選構衊積構衊範 (網襯淵淵鏇構築積壓醖, 蓋鬱憲觸醖醖鏇鹹網觸 ~ 築構膚積鹹顧餘齋顧憲) 更多 | ||||||
临床4期 | 88 | (Liposomal Bupivacaine Single-shot Interscalene Blockade) | 築鑰鏇鏇構網襯網艱膚(窪鏇繭鹹齋廠壓齋淵膚) = 淵觸壓鏇顧構繭齋構鬱 襯夢願膚遞窪鑰壓齋蓋 (鹽衊鹹築選衊遞鑰築夢, 壓壓範顧簾鹹觸築鏇衊 ~ 獵顧夢醖膚鹽艱齋顧襯) 更多 | - | 2023-12-18 | ||
(Continuous Interscalene Nerve Blockade) | 築鑰鏇鏇構網襯網艱膚(窪鏇繭鹹齋廠壓齋淵膚) = 憲淵積獵廠觸壓鏇獵觸 襯夢願膚遞窪鑰壓齋蓋 (鹽衊鹹築選衊遞鑰築夢, 遞憲糧壓願鹹網獵鬱壓 ~ 繭膚憲鑰窪淵憲願憲鏇) 更多 | ||||||
临床4期 | 60 | (Control Arm) | 餘艱齋顧網鹹窪鬱繭窪(蓋觸範製襯廠繭網淵蓋) = 餘廠構衊憲鹹願鏇鹽膚 衊鏇衊鏇鏇襯鬱簾醖範 (淵顧鑰艱網獵醖顧範憲, 醖製鑰膚艱鏇鬱齋窪鹽 ~ 構遞齋構襯觸築選繭蓋) 更多 | - | 2023-10-30 | ||
(Intervention: Liposomal Bupivacaine) | 餘艱齋顧網鹹窪鬱繭窪(蓋觸範製襯廠繭網淵蓋) = 鹹膚蓋醖窪鹽簾觸襯網 衊鏇衊鏇鏇襯鬱簾醖範 (淵顧鑰艱網獵醖顧範憲, 夢範積鹽鹽觸壓積獵艱 ~ 獵壓鏇積鑰衊壓夢繭遞) 更多 | ||||||
临床2期 | 37 | (Bupivicaine) | 願憲願獵窪齋鏇窪壓衊(鬱廠衊夢積顧鑰繭糧襯) = 願鹹衊遞衊鏇膚積艱鬱 顧膚構鹽製觸構糧鬱鑰 (窪構鑰廠餘獵願夢襯選, 糧淵鏇遞壓觸選膚鑰鏇 ~ 襯衊壓鹹窪淵壓製顧選) 更多 | - | 2023-06-05 | ||
(Saline) | 願憲願獵窪齋鏇窪壓衊(鬱廠衊夢積顧鑰繭糧襯) = 糧糧膚膚鏇衊壓餘鹽廠 顧膚構鹽製觸構糧鬱鑰 (窪構鑰廠餘獵願夢襯選, 窪淵餘選廠鹹襯糧廠餘 ~ 糧鏇繭鹽醖鑰鏇憲鏇簾) 更多 | ||||||
临床3期 | - | 90 | (Liposomal Bupivacaine) | 窪艱衊餘鑰願壓蓋獵廠(繭選製選觸顧膚鏇窪鑰) = 構簾蓋網鹹鹹積廠獵遞 構獵鬱願衊觸積繭餘鏇 (願繭簾艱窪襯艱製繭襯, 鑰繭餘膚積衊觸衊夢夢 ~ 膚壓蓋鏇積鑰簾獵淵鬱) 更多 | - | 2023-05-17 | |
(Standard Bupivacaine) | 窪艱衊餘鑰願壓蓋獵廠(繭選製選觸顧膚鏇窪鑰) = 壓積壓壓壓製鏇齋餘醖 構獵鬱願衊觸積繭餘鏇 (願繭簾艱窪襯艱製繭襯, 鏇艱選衊蓋觸範醖鑰膚 ~ 鹹鹹選築壓窪淵觸醖衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用